AR125488A1 - Proteínas de unión biespecíficas de pd-1 y de tigit, y usos de las mismas - Google Patents
Proteínas de unión biespecíficas de pd-1 y de tigit, y usos de las mismasInfo
- Publication number
- AR125488A1 AR125488A1 ARP220101126A ARP220101126A AR125488A1 AR 125488 A1 AR125488 A1 AR 125488A1 AR P220101126 A ARP220101126 A AR P220101126A AR P220101126 A ARP220101126 A AR P220101126A AR 125488 A1 AR125488 A1 AR 125488A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- amino acid
- acid sequence
- binding
- domain
- Prior art date
Links
- 102000014914 Carrier Proteins Human genes 0.000 title abstract 9
- 108091008324 binding proteins Proteins 0.000 title abstract 9
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 title abstract 5
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 12
- 101710090983 T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 abstract 4
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La divulgación se refiere a proteínas de unión, incluidos anticuerpos, que se unen a la proteína de muerte programada 1 (PD-1) y al inmunorreceptor de linfocitos T con dominios Ig e ITIM (TIGIT). La divulgación también proporciona composiciones que comprenden tales proteínas de unión y moléculas de ácido nucleico que codifican tales proteínas de unión. La divulgación se refiere además a métodos para tratar un trastorno o una afección utilizando tales proteínas de unión. Reivindicación 1: Una proteína de unión biespecífica que se une específicamente a PD-1 y a TIGIT que comprende: a) un primer dominio de unión que se une específicamente a PD-1, en donde el primer dominio de unión comprende un dominio variable de cadena pesada que comprende una HCDR1 que tiene la secuencia de aminoácidos de SEQ ID Nº 1, una HCDR2 que tiene la secuencia de aminoácidos de SEQ ID Nº 2 y una HCDR3 que tiene la secuencia de aminoácidos de SEQ ID Nº 3, y un dominio variable de cadena ligera que comprende una LCDR1 que tiene la secuencia de aminoácidos de SEQ ID Nº 4, una LCDR2 que tiene la secuencia de aminoácidos de SEQ ID Nº 5 y una LCDR3 que tiene la secuencia de aminoácidos de SEQ ID Nº 6; y b) un segundo dominio de unión que se une específicamente a TIGIT, en donde el segundo dominio de unión comprende un dominio variable de cadena pesada que comprende una HCDR1 que tiene la secuencia de aminoácidos de SEQ ID Nº 11, una HCDR2 que tiene la secuencia de aminoácidos de SEQ ID Nº 12 y una HCDR3 que tiene la secuencia de aminoácidos de SEQ ID Nº 13, y un dominio variable de cadena ligera que comprende una LCDR1 que tiene la secuencia de aminoácidos de SEQ ID Nº 14, una LCDR2 que tiene la secuencia de aminoácidos de SEQ ID Nº 15 y una LCDR3 que tiene la secuencia de aminoácidos de SEQ ID Nº 16. Reivindicación 35: Una composición farmacéutica que comprende proteína de unión biespecífica de una cualquiera de las reivindicaciones 1 - 34 y un vehículo farmacéuticamente aceptable. Reivindicación 37: Un ácido nucleico que comprende una secuencia de nucleótidos que codifica la proteína de unión biespecífica de una cualquiera de las reivindicaciones 1 - 34. Reivindicación 42: Un vector que comprende el ácido nucleico de una cualquiera de las reivindicaciones 37 - 41. Reivindicación 43: Una célula hospedadora que comprende el vector de la reivindicación 42. Reivindicación 46: Un anticuerpo biespecífico expresado por la célula hospedadora de una cualquiera de las reivindicaciones 43 - 45. Reivindicación 53: Una proteína de unión biespecífica como se define en una cualquiera de las reivindicaciones 1 - 34 para usar en terapia.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163182156P | 2021-04-30 | 2021-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125488A1 true AR125488A1 (es) | 2023-07-19 |
Family
ID=83846748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101126A AR125488A1 (es) | 2021-04-30 | 2022-04-29 | Proteínas de unión biespecíficas de pd-1 y de tigit, y usos de las mismas |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11939382B2 (es) |
| EP (1) | EP4329803A2 (es) |
| JP (1) | JP2024517558A (es) |
| KR (1) | KR20240004300A (es) |
| CN (1) | CN117202933A (es) |
| AR (1) | AR125488A1 (es) |
| AU (1) | AU2022265633A1 (es) |
| BR (1) | BR112023020193A2 (es) |
| CA (1) | CA3212025A1 (es) |
| CL (1) | CL2023002928A1 (es) |
| CO (1) | CO2023013140A2 (es) |
| CR (1) | CR20230476A (es) |
| EC (1) | ECSP23074489A (es) |
| IL (1) | IL307284A (es) |
| TW (1) | TW202309086A (es) |
| WO (1) | WO2022229919A2 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023215719A1 (en) * | 2022-05-02 | 2023-11-09 | Arcus Biosciences, Inc. | Anti-tigit antibodies and uses of the same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR108377A1 (es) * | 2016-05-06 | 2018-08-15 | Medimmune Llc | Proteínas de unión biespecíficas y sus usos |
| MY194032A (en) * | 2016-08-17 | 2022-11-09 | Compugen Ltd | Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof |
| US11713353B2 (en) * | 2018-01-15 | 2023-08-01 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against PD-1 |
-
2022
- 2022-04-29 CA CA3212025A patent/CA3212025A1/en active Pending
- 2022-04-29 US US17/661,307 patent/US11939382B2/en active Active
- 2022-04-29 EP EP22795127.4A patent/EP4329803A2/en active Pending
- 2022-04-29 KR KR1020237035068A patent/KR20240004300A/ko unknown
- 2022-04-29 CN CN202280029448.9A patent/CN117202933A/zh active Pending
- 2022-04-29 AR ARP220101126A patent/AR125488A1/es unknown
- 2022-04-29 BR BR112023020193A patent/BR112023020193A2/pt unknown
- 2022-04-29 AU AU2022265633A patent/AU2022265633A1/en active Pending
- 2022-04-29 TW TW111116547A patent/TW202309086A/zh unknown
- 2022-04-29 WO PCT/IB2022/053997 patent/WO2022229919A2/en active Application Filing
- 2022-04-29 IL IL307284A patent/IL307284A/en unknown
- 2022-04-29 CR CR20230476A patent/CR20230476A/es unknown
- 2022-04-29 JP JP2023558151A patent/JP2024517558A/ja active Pending
-
2023
- 2023-09-29 EC ECSENADI202374489A patent/ECSP23074489A/es unknown
- 2023-09-29 CL CL2023002928A patent/CL2023002928A1/es unknown
- 2023-10-02 CO CONC2023/0013140A patent/CO2023013140A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240004300A (ko) | 2024-01-11 |
| IL307284A (en) | 2023-11-01 |
| EP4329803A2 (en) | 2024-03-06 |
| TW202309086A (zh) | 2023-03-01 |
| CN117202933A (zh) | 2023-12-08 |
| CL2023002928A1 (es) | 2024-04-12 |
| US11939382B2 (en) | 2024-03-26 |
| CA3212025A1 (en) | 2022-11-03 |
| AU2022265633A1 (en) | 2023-09-28 |
| CR20230476A (es) | 2024-01-30 |
| WO2022229919A3 (en) | 2023-01-05 |
| WO2022229919A2 (en) | 2022-11-03 |
| CO2023013140A2 (es) | 2023-10-19 |
| ECSP23074489A (es) | 2023-12-29 |
| BR112023020193A2 (pt) | 2023-11-14 |
| AU2022265633A9 (en) | 2024-01-25 |
| US20220411509A1 (en) | 2022-12-29 |
| JP2024517558A (ja) | 2024-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126242A2 (es) | Tratamiento del cáncer utilizando receptores de antígenos quiméricos | |
| AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
| PE20210132A1 (es) | Anticuerpos anti-cd3 y usos de estos | |
| AR111361A1 (es) | Anticuerpos biespecíficos de unión específica a pd1 y lag3 | |
| AR117727A1 (es) | Anticuerpos que se unen a cd3 | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| AR072039A1 (es) | Anticuerpos contra el virus de la hepatitis c | |
| EA201990570A1 (ru) | Моноклональное антитело против pd1, его фармацевтическая композиция и их применение | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| AR126019A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| BR112017027877A2 (pt) | anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico isolado, vetor, célula hospedeira, método para preparar o anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, cepa de célula hibridoma lt005, conjugado, conjugado de anticorpo bifuncional, anticorpo multiespecífico, composição farmacêutica e uso do anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo | |
| CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
| AR109264A1 (es) | Proteínas de unión semejantes a anticuerpo biespecíficas que se unen específicamente a cd3 y cd123 | |
| PE20240802A1 (es) | Anticuerpos multiespecificos con especificidad para il-4r e il-31 | |
| AR086984A1 (es) | Anticuerpo anti-cxcr4 con funciones efectoras y su uso en el tratamiento del cancer | |
| AR104906A1 (es) | Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos | |
| AR123480A1 (es) | Moléculas de unión terapéuticas | |
| AR110967A1 (es) | Anticuerpos miméticos fgf21 y su uso | |
| AR125488A1 (es) | Proteínas de unión biespecíficas de pd-1 y de tigit, y usos de las mismas | |
| BR112022021397A2 (pt) | Anticorpo anti-cd73, polipeptídeo isolado, molécula de ácido nucleico, vetor, célula hospedeira, conjugado, proteína de fusão ou anticorpo multiespecífico, kit, composição farmacêutica, uso do anticorpo e linhagem celular de hibridoma | |
| PE20231080A1 (es) | Anticuerpos que se unen a cd3 y cd19 | |
| AR124289A1 (es) | Composiciones de agentes de unión a antígenos de guanilato ciclasa c (gcc) y métodos de uso de estos | |
| PE20232050A1 (es) | Anticuerpos anti-cd19 y estructuras car-t | |
| PE20240086A1 (es) | Anticuerpos anti-cd122 y usos de estos | |
| AR127271A1 (es) | Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos |